Delanaye P, Scheen AJ. Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opin Pharmacother. 2019; 20(3):277-94.
Scheen AJ, Delanaye P. Inhibiteurs des SGLT2 : focus sur le rein et la néphroprotection. Rev Med Suisse. 2021; 17(747):1397-403.
Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone alockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008; 51(2):199-211.
Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020; 10(10):CD007004.
Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012; 7(8):1385-403.
Heinig R, Gerisch M, Engelen A, Nagelschmitz J, Loewen S. Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo. Eur J Drug Metab Pharmacokinet. 2018; 43(6):715-27.
Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from firstin-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016; 30(2):172-84.
Gerisch M, Heinig R, Engelen A, et al. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro. Drug Metab Dispos. 2018; 46(11):1546-55.
Wendl T, Frechen S, Gerisch M, Heinig R, Eissing T. Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone. CPT Pharmacometrics Syst Pharmacol. 2022; 11(2):199-211.
Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014; 64(1):69-78.
Barrera-Chimal J, Estrela GR, Lechner SM, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 2018; 93(6):1344-55.
Kolkhof P, Hartmann E, Freyberger A, et al. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. Am J Nephrol. 2021; 52(8):642-52.
Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Hear J. 2013; 34(31):2453-63.
Bakris GL, Agarwal R, Chan JC, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy :A Randomized Clinical Trial. JAMA. 2015; 314(9):884-94.
Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020; 383(23):2219-29.
Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021; 385(24):2252-63.
Filippatos G, Pitt B, Agarwal R, et al. Finerenone in patients with CKD and T2D with and without heart failure: A prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Hear Fail. 2022. DOI:10.1002/ejhf.2469.
Rossing P, Burgess E, Agarwal R, et al. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022; 45(4):888-97.
Filippatos G, Anker SD, Agarwal R, et al. Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021; 143(6):540-52.
Ruilope LM, Pitt B, Anker SD, et al. Kidney outcomes with finerenone: An analysis from the FIGARO-DKD study. Nephrol Dial Transpl. 2022; gfac157. DOI: 10.1093/ndt/gfac157.
Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Hear J. 2022; 43(6):474-84.
Neuen BL, Oshima M, Agarwal R, et al. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials. Circulation. 2022; 145(19):1460-70.
Neuen BL, Jardine MJ. SGLT2 inhibitors and finerenone: one or the other or both?. Nephrol Dial Transpl. 2022; 37(7):1209-11.
Agarwal R, Anker SD, Filippatos G, et al. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transpl. 2022; 37(7):1261-9.
Delanaye P, Scheen AJ. The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection. Diabetes Metab. 2021; 47(6):101285.
Provenzano M, Jongs N, Vart P, et al. The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. Kidney Int Rep. 2021; 7(3):436-43.
Rossing P, Filippatos G, Agarwal R, et al. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney Int Rep. 2022; 7(1):36-45.
Agarwal R, Joseph A, Anker SD, et al. Hyperkalemia Risk with Finerenone : Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022; 33(1):225-37.
